KRP-M223 / Kyorin, Novartis - LARVOL DELTA

Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin (FierceBiotech) - "Novartis is paying Kyorin $55 million upfront for exclusive global rights to develop, manufacture and commercialize KRP-M223, a preclinical mast-cell-targeting candidate for chronic spontaneous urticaria (CSU)....Kyorin could also net up to $777.5 million if certain milestones are met..."

Licensing / partnership • Chronic Spontaneous Urticaria • Immunology